Payors Urge 1st Circ. To Revive Pfizer Neurontin MDL Claims
Health plans and other third-party payors accusing Pfizer Inc. of fraudulently promoting epilepsy drug Neurontin to treat bipolar disorder on Monday told the First Circuit their claims had been improperly dismissed...To view the full article, register now.
Already a subscriber? Click here to view full article